header image
Tagging the key biologic mediators of neurodegeneration

The vision of C2N Diagnostics is to catalyze the discovery of new therapeutics and methods of early detection for neurodegenerative diseases. Using a proprietary metabolic labeling assay developed at the Washington University School of Medicine in Saint Louis, Missouri, C2N Diagnostics can measure the production and clearance of peptides, proteins and other biomolecules directly in the spinal fluid and brain of humans and animals. This capability could be instrumental in the identification, development, and optimization of new molecules that target the key biologic mediators of pathogenesis for diseases like Alzheimer's, Parkinson's Disease, Huntington's Disease, and others.